

# Elisabetta Pupillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9298190/publications.pdf>

Version: 2024-02-01

59  
papers

14,884  
citations

218677

26  
h-index

144013

57  
g-index

62  
all docs

62  
docs citations

62  
times ranked

16509  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
2	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
3	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1043-1048.	21.4	494
4	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	13.7	335
5	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	13.7	330
6	Burden of Neurological Disorders Across the US From 1990-2017. <i>JAMA Neurology</i> , 2021, 78, 165.	9.0	262
7	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	21.4	223
8	Long-term survival in amyotrophic lateral sclerosis: A population-based study. <i>Annals of Neurology</i> , 2014, 75, 287-297.	5.3	141
9	Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. <i>Nature Communications</i> , 2017, 8, 14774.	12.8	114
10	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 1-10.	2.1	107
11	Lithium carbonate in amyotrophic lateral sclerosis. <i>Neurology</i> , 2010, 75, 619-625.	1.1	90
12	Physical activity and amyotrophic lateral sclerosis: A European population-based case-control study. <i>Annals of Neurology</i> , 2014, 75, 708-716.	5.3	79
13	Barriers toward epilepsy surgery. A survey among practicing neurologists. <i>Epilepsia</i> , 2012, 53, 35-43.	5.1	78
14	The perceived burden of epilepsy: Impact on the quality of life of children and adolescents and their families. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2015, 24, 93-101.	2.0	72
15	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 397-405.	1.7	68
16	Trauma and amyotrophic lateral sclerosis: a case-control study from a population-based registry. <i>European Journal of Neurology</i> , 2012, 19, 1509-1517.	3.3	63
17	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1289-1297.	0.7	55
18	Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 98-105.	1.7	54

#	ARTICLE	IF	CITATIONS
19	Italy's health performance, 1990â€“2017: findings from the Global Burden of Disease Study 2017. <i>Lancet Public Health</i> , The, 2019, 4, e645-e657.	10.0	54
20	Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 641-651.	0.9	51
21	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. <i>American Journal of Epidemiology</i> , 2011, 174, 1002-1008.	3.4	50
22	Multicentre, cross-cultural, population-based, caseâ€“control study of physical activity as risk factor for amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 797-803.	1.9	45
23	Acceptance of epilepsy surgery among adults with epilepsy â€” What do patients think?. <i>Epilepsy and Behavior</i> , 2012, 24, 352-358.	1.7	38
24	Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP). <i>Neurological Sciences</i> , 2015, 36, 1567-1574.	1.9	35
25	Focus on the heterogeneity of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 485-495.	1.7	32
26	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 99.	2.9	30
27	Increased risk and early onset of ALS in professional players from Italian Soccer Teams. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 403-409.	1.7	30
28	Amyotrophic lateral sclerosis and food intake. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 267-274.	1.7	29
29	Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: A population based cross-sectional study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 324-330.	1.7	26
30	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 118-125.	1.7	26
31	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 11-19.	1.9	26
32	Acceptance of epilepsy surgery in the pediatric age â€” What the parents think and what the doctors can do. <i>Epilepsy and Behavior</i> , 2013, 29, 112-120.	1.7	24
33	Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy. <i>Neuroepidemiology</i> , 2016, 47, 38-45.	2.3	21
34	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. <i>Journal of Neurology</i> , 2022, 269, 2080-2098.	3.6	21
35	Knowledge and attitudes towards epilepsy in Zambia: A questionnaire survey. <i>Epilepsy and Behavior</i> , 2014, 34, 42-46.	1.7	20
36	Educational and Exercise Intervention to Prevent Falls and Improve Participation in Subjects With Neurological Conditions: The NEUROFALL Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2019, 10, 865.	2.4	20

#	ARTICLE	IF	CITATIONS
37	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quit: Euro-MOTOR. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 33-39.	1.9	20
38	Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 854-860.	1.9	17
39	Satisfaction with antiepileptic drugs in children and adolescents with newly diagnosed and chronic epilepsy. <i>Epilepsy Research</i> , 2012, 100, 142-151.	1.6	13
40	Mobility Disorders in Stroke, Parkinson Disease, and Multiple Sclerosis. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2020, 99, 41-47.	1.4	12
41	Migraine-specific quality of life questionnaire and relapse of medication overuse headache. <i>BMC Neurology</i> , 2015, 15, 85.	1.8	10
42	The role of single-nucleotide variants of the energy metabolism-linked genes <i>SIRT3</i>, <i>PPARGC1A</i>, and <i>APOE</i> in amyotrophic lateral sclerosis risk. <i>Genes and Genetic Systems</i> , 2016, 91, 301-309.	0.7	10
43	Non-self-sufficiency as a primary outcome measure in ALS trials. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 77-84.	1.7	9
44	Plasma amino acids patterns and age of onset of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 371-375.	1.7	8
45	Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 385-388.	1.7	7
46	Voluptuary Habits and Risk of Frontotemporal Dementia: A Case Control Retrospective Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 335-340.	2.6	6
47	Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study. <i>Neurological Sciences</i> , 2022, 43, 5133-5141.	1.9	6
48	Is firstly diagnosed ALS really ALS? Results of a population-based study with long-term follow-up. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 221-226.	1.7	4
49	Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy. <i>Neurobiology of Aging</i> , 2020, 92, 153.e1-153.e5.	3.1	4
50	Trends in survival of ALS from a population-based registry. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 344-352.	1.7	4
51	Geographical clusters of amyotrophic lateral sclerosis and the Bradford Hill criteria. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 329-343.	1.7	3
52	Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. <i>Prion</i> , 2022, 16, 66-77.	1.8	3
53	Peculiarities of Neurological Disorders and Study Designs. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 8-23.	2.8	1
54	Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues". <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 1688-1689.	0.9	1

#	ARTICLE	IF	CITATIONS
55	ALS incidence and population aging in Northern Italy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 236-241.	1.7	1
56	Drug treatments and interactions, disease progression and quality of life in ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 415-423.	1.7	1
57	Coffee and Amyotrophic Lateral Sclerosis. , 2015, , 429-434.		0
58	Author response to a Letter to the Editor entitled: Preventive effect of coffee and tea on amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 618-618.	1.7	0
59	ALSUntangled 53: Carnitine supplements. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 477-483.	1.7	0